Sep 19th 2013 - Edison Investment Research today published a report on Derma Sciences entitled "Complete Wound Care". In summary, the report says:
Using cash generated from the slow-growing but stable traditional wound care business unit, Derma Sciences was able to invest in its advanced wound care unit, which has seen an annual growth rate of 40-55%. The company has also started a Phase III trial of DSC127, a drug developed for diabetic foot ulcers, which could generate peak sales of $400m+, and is the largest value driver for the stock. We think Derma Sciences’ shares are undervalued based on its revenue growth perspectives and the risked potential of DSC127.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »